Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hahnemann laboratories, inc. - prunus laurocerasus leaf (unii: f26p2d4757) (prunus laurocerasus leaf - unii:f26p2d4757) -

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - imiglucerase 400 u (per 10 ml -biological product from recombinant cho cells);   - powder for infusion - 40 u/ml - active: imiglucerase 400 u (per 10 ml -biological product from recombinant cho cells)   excipient: citric acid monohydrate mannitol nitrogen polysorbate 80 sodium citrate dihydrate - cerezyme is indicated for long - term enzyme replacement therapy for patients with a confirmed diagnosis of non-neuronopathic (type 1) or chronic neuronopathic (type 3) gaucher disease who exhibit clinically significant non-neurological manifestations of the disease. the non-neurological manifestations of gaucher disease include one or more of the following conditions: a) anaemia; b) thrombocytopenia; c) bone disease; d) hepatomegaly or splenomegaly.

Европска Унија - Енглески - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velaglucerase alfa - gaucher disease - other alimentary tract and metabolism products, - vpriv is indicated for long-term enzyme-replacement therapy (ert) in patients with type-1 gaucher disease.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) - powder for injection - 200 u - active: taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) excipient: citric acid mannitol polysorbate 80 sodium citrate dihydrate - elelyso is indicated for long-term enzyme replacement therapy for adult and paediatric patients with a confirmed diagnosis of type 1 gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anaemia, thrombocytopenia.

Канада - Енглески - Health Canada

pfizer canada ulc - taliglucerase alfa - powder for solution - 200unit - taliglucerase alfa 200unit - enzymes

Канада - Енглески - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - imiglucerase - powder for solution - 200unit - imiglucerase 200unit - enzymes

Канада - Енглески - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - imiglucerase - powder for solution - 400unit - imiglucerase 400unit - enzymes

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - imiglucerase - powder for solution for infusion - 400unit

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - velaglucerase alfa - powder for solution for infusion - 400unit

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

takeda new zealand limited - velaglucerase alfa 400 u;   - powder for infusion concentrate - 400 u - active: velaglucerase alfa 400 u   excipient: citric acid monohydrate polysorbate 20 sodium citrate dihydrate sucrose - vpriv is indicated for long-term enzyme replacement therapy (ert) for paediatric and adult patients with type i gaucher disease.